Reaction
Skin Hypopigmentation reporting signals
As of the last recalculation, Skin Hypopigmentation appears in 1,731 FAERS reports alongside 23 co-occurring drug terms. The strongest observed disproportionality signal is ADAPALENE (PRR 61.6).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Adapalene | 610 | 61.6 | 61.9 |
| Salicylic Acid | 175 | 44.1 | 44.3 |
| Sulfur | 29 | 42.1 | 42.2 |
| Ribociclib | 63 | 24.9 | 24.9 |
| Triamcinolone Acetonide | 59 | 23.7 | 23.8 |
| Triamcinolone Acetonide Ointment Usp, 0.05% | 43 | 22.6 | 22.7 |
| Crisaborole | 14 | 17.7 | 17.7 |
| Letrozole Tablets | 62 | 16.0 | 16.1 |
| Pazopanib Hydrochloride | 34 | 15.4 | 15.4 |
| Vemurafenib | 13 | 13.1 | 13.1 |
| Imatinib | 19 | 13.1 | 13.1 |
| Letrozole | 62 | 12.5 | 12.5 |
| Clobetasol Propionate Ointment Usp, 0.05% | 10 | 11.7 | 11.7 |
| Clobetasol Propionate | 9 | 10.5 | 10.5 |
| Dapsone | 9 | 10.2 | 10.2 |
| Nemolizumab-Ilto | 9 | 8.6 | 8.6 |
| Encorafenib | 4 | 4.9 | 4.9 |
| Botulinum Toxin Type A | 4 | 3.9 | 3.9 |
| Rimegepant Sulfate | 4 | 3.8 | 3.8 |
| Cabozantinib | 15 | 3.8 | 3.8 |
| Ipilimumab | 13 | 3.6 | 3.6 |
| Dasatinib | 11 | 3.6 | 3.6 |
| Dupilumab | 110 | 2.9 | 2.9 |